ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma.
Journal
Bone marrow transplantation
ISSN: 1476-5365
Titre abrégé: Bone Marrow Transplant
Pays: England
ID NLM: 8702459
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
received:
04
03
2021
accepted:
25
03
2021
revised:
08
03
2021
pubmed:
21
8
2021
medline:
11
3
2022
entrez:
20
8
2021
Statut:
ppublish
Résumé
Autologous (auto-) or allogeneic (allo-) hematopoietic cell transplantation (HCT) are accepted treatment modalities for mantle cell lymphoma (MCL). Recently, chimeric antigen receptor (CAR) T-cell therapy received approval for MCL; however, its exact place and sequence in relation to HCT is unclear. The ASTCT, CIBMTR, and the EBMT, jointly convened an expert panel to formulate consensus recommendations for role, timing, and sequencing of auto-, allo-HCT, and CAR T-cell therapy for patients with newly diagnosed and relapsed/refractory (R/R) MCL. The RAND-modified Delphi method was used to generate consensus statements. Seventeen consensus statements were generated; in the first-line setting auto-HCT consolidation represents standard-of-care in eligible patients, whereas there is no clear role of allo-HCT or CAR T-cell therapy, outside of a clinical trial. In the R/R setting, the preferential option is CAR T-cell therapy especially in MCL failing or intolerant to at least one Bruton's tyrosine kinase inhibitor, while allo-HCT is recommended if CAR T-cell therapy has failed or is not feasible. In the absence of contemporary evidence-based data, the panel found RAND-modified Delphi methodology effective in providing a formal framework for developing consensus recommendations for the timing and sequence of cellular therapies for MCL.
Identifiants
pubmed: 34413469
doi: 10.1038/s41409-021-01288-9
pii: 10.1038/s41409-021-01288-9
pmc: PMC8639670
mid: NIHMS1687814
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
2911-2921Subventions
Organisme : NHLBI NIH HHS
ID : U24 HL138660
Pays : United States
Organisme : U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (National Cancer Institute Division of Cancer Epidemiology and Genetics)
ID : U24CA076518
Informations de copyright
© 2021. The Author(s).
Références
Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. WHO Classification of Tumours, Revised 4th Edition, Volume 2.2. p. 215–344.
Martin P, Chadburn A, Christos P, Weil K, Furman R, Ruan J, et al. Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol. 2009;27:1209–13.
doi: 10.1200/JCO.2008.19.6121
Dreyling M, Campo E, Hermine O, Jerkeman M, Le Gouill S, Rule S, et al. ESMO Guidelines Committee. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv62–iv71.
doi: 10.1093/annonc/mdx223
Robinson S, Dreger P, Caballero D, Corradini P, Geisler C, Ghielmini M, et al. European MCL Network and the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation. The EBMT/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma. Leukemia. 2015;29:464–73.
doi: 10.1038/leu.2014.223
Maddocks K. Update on mantle cell lymphoma. Blood. 2018;132:1647–56.
doi: 10.1182/blood-2018-03-791392
Eskelund CW, Dahl C, Hansen JW, Westman M, Kolstad A, Pedersen L, et al. TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. Blood. 2017;130:1903–10. https://doi.org/10.1182/blood-2017-04-779736 .
doi: 10.1182/blood-2017-04-779736
Jerkeman M, Eskelund CW, Hutchings M, Räty R, Wader K, Laurellet A. al. Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial. Lancet Haematol. 2018;5:e109–e116.
doi: 10.1016/S2352-3026(18)30018-8
Aukema SM, Hoster E, Rosenwald A, Canoni D, Delfau-Larue M, Rymkiewicz G, et al. Expression of TP53 is associated with outcome of MCL independent of MIPI and Ki-67 in trials of the European-MCL Network. Blood. 2018;131:417–20.
doi: 10.1182/blood-2017-07-797019
Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl B, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N. Engl J Med. 2013;369:507–16.
doi: 10.1056/NEJMoa1306220
Wang ML, Munoz J, Goy A, Locke F, Jacobson C, Hill B, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N. Engl J Med. 2020;382:1331–42.
doi: 10.1056/NEJMoa1914347
Dreyling M, Lenz G, Hoster E, Gisselbrecht C, Schmits R, Metzneret B. al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood. 2005;105:2677–84.
doi: 10.1182/blood-2004-10-3883
Fenske TS, Zhang MJ, Carreras J, Ayala E, Burns L, Cashen A, et al. Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality. J Clin Oncol. 2014;32:273–81.
doi: 10.1200/JCO.2013.49.2454
Zoellner A, Unterhalt M, Stilgenbauer S, Hübel K, Thieblemont C, Metzner B, et al. Autologous stem cell transplantation in first remission significantly prolongs progression-free and overall survival in mantle cell lymphoma. Int Conf Malig Lymphoma, Hematological Oncol. 2019;37:43–44.
Gerson JN, Handorf E, Villa D, Gerrie A, Chapani P, Li S, et al. Survival outcomes of younger patients with mantle cell lymphoma treated in the rituximab era. J Clin Oncol. 2019;37:471–80.
doi: 10.1200/JCO.18.00690
LaCasce A, Vandergrift J, Rodriguez M, Abel G, Crosby A, Czuczman M, et al. Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database. Blood. 2012;119:2093–9.
doi: 10.1182/blood-2011-07-369629
Hamadani M, Saber W, Ahn K, Carreras J, Cairo M, Fenske T, et al. Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the center for international blood and marrow transplant research. Biol Blood Marrow Transpl. 2013;19:625–31. https://doi.org/10.1016/j.bbmt.2013.01.009.
doi: 10.1016/j.bbmt.2013.01.009.
Krüger WH, Hirt C, Basara N, Sayer H, Behre G, Fischer T, et al. Allogeneic stem cell transplantation for mantle cell lymphoma-final report from the prospective trials of the East German Study Group Haematology/Oncology (OSHO). Ann Hematol. 2014;93:1587–97.
doi: 10.1007/s00277-014-2087-z
Le Gouill S, Thieblemont C, Oberic L, Moreau A, Bouabdallah K, Dartigeas C, et al. Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma. N. Engl J Med. 2017;377:1250–60.
doi: 10.1056/NEJMoa1701769
Owen C, Berinstein NL, Christofides A, Sehn L. Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma. Curr Oncol. 2019;26:e233–e240. https://doi.org/10.3747/co.26.4345 .
doi: 10.3747/co.26.4345
pubmed: 31043832
pmcid: 6476444
Loblaw DA, Prestrud A, Somerfield M, Oliver T, Brouwers M, Nam R, et al. American Society of Clinical Oncology Clinical Practice Guidelines: formal systematic review-based consensus methodology. Clin Oncol. 2012;30:3136–40.
Murphy MK, Black NA, Lamping DL, McKee CM, Sanderson CF, Askham J, et al. Consensus development methods, and their use in clinical guideline development. Health Technol Assess. 1998;2:i–iv.
pubmed: 9561895
Ramakrishna N, Temin S, Chandarlapaty S, Crews J, Davidson N, Esteva F, et al. Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2–positive breast cancer and brain metastases: American society of clinical oncology clinical practice guideline. J Clin Oncol. 2014;32:12100–8. https://doi.org/10.1200/JCO.2013.54.0955 .
doi: 10.1200/JCO.2013.54.0955
Berkman ND, Lohr KN, Ansari MT, Balk E, Kane R, McDonagh MS, et al. Grading the strength of a body of evidence when assessing health care interventions: An EPC update. J Clin Epidemiol. 2015;68:1312–24. https://doi.org/10.1016/j.jclinepi.2014.11.023 .
Geisler CH, Kolstad A, Laurell A, Jerkeman M, Raty R, Andersen N, et al. Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur. Br J Haematol. 2012;158:355–62. https://doi.org/10.1111/j.1365-2141.2012.09174.x .
doi: 10.1111/j.1365-2141.2012.09174.x
pubmed: 22640180
Evens AM, Winter JN, Hou N, Nelson B, Rademaker A, Patton D, et al. A phase II clinical trial of intensive chemotherapy followed by consolidative stem cell transplant: Long-term follow-up in newly diagnosed mantle cell lymphoma. Br J Haematol. 2008;140:385–93.
doi: 10.1111/j.1365-2141.2007.06908.x
Hermine O, Hoster E, Walewski J, Bosly A, Stilgenbauer S, Thieblemont C, et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet. 2016;388:565–75.
doi: 10.1016/S0140-6736(16)00739-X
Chhabra S, Thapa B, Szabo A, Konings S, D’Souza A, Dhakal B, et al. Utilization and cost implications of hematopoietic progenitor cells stored for a future salvage autologous transplantation or stem cell boost in myeloma patients. Biol Blood Marrow Transpl. 2020;26:2011–7. https://doi.org/10.1016/j.bbmt.2020.07.019 .
doi: 10.1016/j.bbmt.2020.07.019
Damon LE, Johnson JL, Niedzwiecki D, Cheson B, Hurd D, Bartlett N. et al. Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle cell lymphoma: CALGB 59909. J Clin Oncol. 2009;27:6101–8. https://doi.org/10.1200/JCO.2009.22.2554 .
doi: 10.1200/JCO.2009.22.2554
pubmed: 19917845
pmcid: 2793032
Hoster E, Klapper W, Hermine O, Kluin-Nelemans H, Walewski J, van Hoof A, et al. Confirmation of the mantle-cell lymphoma international prognostic index in randomized trials of the European mantle-cell lymphoma network. J Clin Oncol. 2014;32:1338–46.
doi: 10.1200/JCO.2013.52.2466
Lin RJ, Ho C, Hilden PD, Barker J, Giralt S, Hamlin P, et al. Allogeneic haematopoietic cell transplantation impacts on outcomes of mantle cell lymphoma with TP53 alterations. Br J Haematol. 2019;184:1006–10.
pubmed: 30537212
Dreyling M, Jurczak W, Jerkeman M, Silva R, Rusconi C, Trneny M, et al. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Lancet. 2016;387:770–8.
doi: 10.1016/S0140-6736(15)00667-4
Khouri IF, Lee MS, Saliba RM, Jun G, Fayad L, Younes A, et al. Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma. J Clin Oncol. 2003;21:4407–12. https://doi.org/10.1200/JCO.2003.05.501 .
doi: 10.1200/JCO.2003.05.501
pubmed: 14645431
Maris MB, Sandmaier BM, Storer BE, Chauncey T, Stuart M, Maziarz R, et al. Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood. 2004;104:3535–42. https://doi.org/10.1182/blood-2004-06-2275 .
doi: 10.1182/blood-2004-06-2275
pubmed: 15304387
Cruz JG, Martino R, Balsalobre P, Heras I, Pinana J, Serrano D, et al. Long-TErm Results of Fludarabine/melphalan as A Reduced-intensity Conditioning Regimen in Mantle Cell Lymphoma: the GELTAMO experience. Ther Adv Hematol. 2011;2:5–10. https://doi.org/10.1177/2040620710396752 .
doi: 10.1177/2040620710396752
pubmed: 23556071
pmcid: 3573392
Kanate AS, Kumar A, Dreger P, Dreyling M, Le Gouill S, Corradini P, et al. Maintenance Therapies for Hodgkin and Non-Hodgkin Lymphomas After Autologous Transplantation: A Consensus Project of ASBMT, CIBMTR, and the Lymphoma Working Party of EBMT. JAMA Oncol. 2019;5:715–22. https://doi.org/10.1001/jamaoncol.2018.6278 .
doi: 10.1001/jamaoncol.2018.6278
pubmed: 30816957
pmcid: 6988125